Associations with baseline visual acuity in 12,414 eyes starting treatment for neovascular AMD

• Published in: Eye (London) Vol. 37; no. 8; pp. 1652 - 1658
• Main Authors: Relton, S. D., Chi, G. C., Lotery, A. J., West, R. M., McKibbin, M.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.06.2023; Nature Publishing Group
• Subjects: 692/499; 692/700/1750; Acuity; Age; Angiogenesis Inhibitors - therapeutic use; Demography; Electronic medical records; Eye; Female; Humans; Laboratory Medicine; Macular degeneration; Medicine; Medicine & Public Health; Morbidity; Ophthalmology; Pedestrians; Pharmaceutical Sciences/Technology; State Medicine; Surgery; Surgical Oncology; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration - drug therapy
• ISSN: 0950-222X; 1476-5454
• DOI: 10.1038/s41433-022-02208-x

Aims To determine baseline visual acuity before the start of treatment for neovascular age-related macular degeneration (AMD), compare median and visual acuity states between treatment sites and investigate the association of socio-demographic and clinical characteristics with baseline acuity. Methods Anonymised demographic and clinical data, collected as part of routine clinical care, were extracted from electronic medical records at treating National Health Service (NHS) Trusts. Analyses were restricted to eyes with baseline visual acuity recorded at treatment initiation. Associations with baseline acuity were investigated using multivariate linear regression. Results Analysis included 12,414 eyes of 9116 patients at 13 NHS Trusts. Median baseline acuity was LogMAR 0.46 (interquartile range = 0.26–0.80) and 34.5% of eyes had good acuity, defined as LogMAR ≤0.3. Baseline acuity was positively associated with second-treated eye status, younger age, lower socio-economic deprivation, independent living, and female sex. There was little evidence of association between baseline acuity and distance to the nearest treatment centre, systemic or ocular co-morbidity. Despite case-mix adjustments, there was evidence of significant variation of baseline visual acuity between sites. Conclusions Despite access to publicly funded treatment within the NHS, variation in visual acuity at the start of neovascular AMD treatment persists. Identifying the characteristics associated with poor baseline acuity, targeted health awareness campaigns, professional education, and pathway re-design may help to improve baseline acuity, the first eye gap, and visual acuity outcomes.